Beren Therapeutics won FDA approval for Lembaz (adrabetadex), a gene-targeting therapy intended for infantile-onset Niemann-Pick disease type C, capping what the report describes as a long development path. The approval marks a new option for a rapidly progressive lysosomal disorder with limited treatments. For investors and clinical teams, the decision also reinforces continued regulatory traction for gene-based therapies targeting inherited metabolic disease—especially where existing standards have not meaningfully altered trajectories.